 Tiziana Life Sciences Ltd NASDAQ:TLSA has announced the presentation of a study entitled, Treatment of Alzheimers disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb at the Alzheimers Association International Conference AAIC The company said that in the study animal models of Alzheimers disease AD demonstrated that microglia activity was restored and cognition was improved following the dosing of intranasal anti-CD3 monoclonal antibody. The study was presented virtually at the AAIC by Dr Howard L. 